A 68-year-old hypertensive man presents with sudden painless blurring of the lower visual field of his right eye. Fundus examination reveals sectoral flame-shaped hemorrhages and cotton wool spots in the superotemporal quadrant, dilated tortuous veins distal to an arteriovenous crossing, and the finding marked **C** in the diagram. Which of the following is the most appropriate first-line pharmacological intervention for this patient's vision loss?
A. Intravitreal dexamethasone implant (Ozurdex) as primary therapy
B. Intravitreal ranibizumab (anti-VEGF) with monthly injections initially
C. Sectoral panretinal photocoagulation
D. Macular grid laser photocoagulation
Explanation
Why Intravitreal ranibizumab (anti-VEGF) is right
The structure marked C is cystoid macular edema (CME) at the fovea, which is the leading cause of vision loss in branch retinal vein occlusion (BRVO). The BRAVO trial established intravitreal ranibizumab as the first-line pharmacological agent for BRVO with macular edema, achieving sustained vision gains of approximately 16–18 letters at 6 months with monthly injections initially, followed by PRN or treat-and-extend regimens. Anti-VEGF agents directly address the pathophysiology of CME by inhibiting vascular endothelial growth factor released from retinal ischemia, reducing capillary permeability and edema.
Why each distractor is wrong
Intravitreal dexamethasone implant (Ozurdex) as primary therapy: While Ozurdex is an effective alternative or adjunct therapy for BRVO-related macular edema, it is not first-line. It is reserved for pseudophakic patients or those not responding to anti-VEGF, and carries significant limitations including cataract formation and intraocular pressure elevation.
Macular grid laser photocoagulation: Grid laser was the standard of care in the BVOS era but is now reserved only for chronic macular edema that is refractory to pharmacotherapy. It is not first-line in the modern anti-VEGF era.
Sectoral panretinal photocoagulation: PRP is indicated only when neovascularization develops (in ischemic BRVO with ≥5 disc areas of non-perfusion), not for macular edema alone. This patient has no mention of neovascularization.
High-YieldNEET PG
BRVO with macular edema → anti-VEGF (ranibizumab or aflibercept) first-line; laser and corticosteroids are alternatives for specific scenarios.
